Messing Edward
Department of Urology, University of Rochester, Rochester, NY 14642, USA.
Urol Oncol. 2007 Jul-Aug;25(4):344-7. doi: 10.1016/j.urolonc.2007.05.012.
Three applications of markers of detection: screening, replacing surveillance cystoscopies, and guiding evaluation of asymptomatic hematuria, are discussed. In one study, repetitive hematuria screening in men age >or=50 effectively shifted the stage of high grade cancers at diagnosis from muscle invasive to earlier ones, reducing bladder cancer, and all cause mortality. This technique is sensitive, but is not terribly specific. Testing other markers alone or in combination with each other and/or hemoglobin screening in similar or higher risk populations is now beginning. Currently, no commercially available marker is sufficiently sensitive to replace all surveillance cystoscopies for low risk bladder cancer, although some cystoscopic examinations can probably be replaced by markers. Available markers are too insensitive for small, high grade cancers to replace any surveillance cystoscopies in this group. No single marker or combination of markers can safely replace cystoscopy in the work-up of patients with microhematuria who are at high risk for harboring bladder cancer. However, markers may be useful for directing which patients age <or=40 with asymptomatic microhematuria without histories of smoking, particularly women, require cystoscopic evaluation.
筛查、替代监测性膀胱镜检查以及指导无症状血尿的评估。在一项研究中,对年龄≥50岁的男性进行重复性血尿筛查,有效地将诊断时高级别癌症的阶段从肌肉浸润性转变为早期阶段,降低了膀胱癌及全因死亡率。该技术具有敏感性,但特异性不强。目前,正在开始在相似或更高风险人群中单独或相互联合检测其他标志物,以及联合血红蛋白筛查。目前,尚无市售标志物对低风险膀胱癌足够敏感,可替代所有监测性膀胱镜检查,不过一些膀胱镜检查可能可被标志物替代。现有标志物对小的高级别癌症不够敏感,无法替代该组患者的任何监测性膀胱镜检查。在对有患膀胱癌高风险的镜下血尿患者进行检查时,没有单一标志物或标志物组合能安全地替代膀胱镜检查。然而,标志物可能有助于指导哪些年龄≤40岁、无症状镜下血尿且无吸烟史的患者,尤其是女性,需要进行膀胱镜评估。